Vol 88, No 7 (2017)
Research paper
Published online: 2017-07-31

open access

Page views 1412
Article views/downloads 1194
Get Citation

Connect on Social Media

Connect on Social Media

Serum levels of soluble interleukin-2 receptor in association with oxidative stress index in patients with different types of HPV

Cenk Nayki, Murat Gunay, Mehmet Kulhan, Umit Nayki, Murat Cankaya, Nur Gozde Kulhan
Pubmed: 28819939
Ginekol Pol 2017;88(7):355-359.

Abstract

Objectives: The aim of this paper is to determine the oxidative–antioxidative status and levels of soluble interleukin-2 recep­tor (sIL-2R) in serum of patients with different types of HPV infections and to compare it with patients who are negative for HPV.

Material and methods: A total of 80 women were divided into three groups as follows: Group 1 consisted of 25 women who were positive for HPV types 16 or 18; Group 2 consisted of 25 women who were positive for other types of HPV includ­ing type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 68; Group 3 consisted of 30 patients who were negative for HPV as a control group. Serum sIL-2R and plasma oxidative stress index (OSI) were analyzed.

Results: Serum sIL-2R levels were significantly higher in group 1 compared to group 2 and 3. OSI was found significantly increased in groups 1 and 2 compared to group 3. Also, we found a weak positive correlation between IL-2R and OSI.

Conclusion: sIL-2R and oxidative stress may have a role in HPV infection, especially in case of high-risk types.

Article available in PDF format

View PDF Download PDF file

References

  1. Wright TC, Richart RM. Role of human papillomavirus in the pathogenesis of genital tract warts and cancer. Gynecol Oncol. 1990; 37(2): 151–164.
  2. Nygård M, Hansen BoT, Dillner J, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One. 2014; 9(2): e88323.
  3. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006; 24 Suppl 1: S1–15.
  4. Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007; 98(10): 1505–1511.
  5. Senapati R, Senapati NN, Dwibedi B. Molecular mechanisms of HPV mediated neoplastic progression. Infect Agent Cancer. 2016; 11: 59.
  6. Poljsak B, Šuput D, Milisav I. Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid Med Cell Longev. 2013; 2013: 956792.
  7. Frazer IH, Tindle RW. Cell-mediated immunity to papillomaviruses. Papillomavirus Report. 1992; 3: 52–58.
  8. Edwards RP, Kuykendall K, Crowley-Nowick P, et al. T lymphocytes infiltrating advanced grades of cervical neoplasia. CD8-positive cells are recruited to invasion. Cancer. 1995; 76(8): 1411–1415.
  9. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990; 113(8): 245–250.
  10. Ung A, Kramer TR, Schiffman M, et al. Soluble interleukin 2 receptor levels and cervical neoplasia: results from a population-based case-control study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 1999; 8(3): 249–253.
  11. Semenzato G, Bambara LM, Biasi D, et al. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol. 1988; 8(6): 447–452.
  12. van Steenbergen HW, van Nies JAB, Ruyssen-Witrand A, et al. IL2RA is associated with persistence of rheumatoid arthritis. Arthritis Res Ther. 2015; 17: 244.
  13. Teraura H, Kotani K, Minami T, et al. The serum concentration of soluble interleukin-2 receptor in patients with Kawasaki disease. Ann Clin Biochem. 2017; 54(2): 209–213.
  14. Nakamura Y, Tanaka Y, Tanaka M, et al. Soluble interleukin-2 receptor index predicts the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. Int J Hematol. 2016; 103(4): 436–443.
  15. Kloster BE, John PA, Miller LE, et al. Soluble interleukin 2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol. 1987; 45(3): 440–446.
  16. Gupta M, Stenson M, O'Byrne M, et al. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma. Ann Oncol. 2016; 27(1): 165–172.
  17. Naumnik W, Chyczewska E, Kovalchuk O, et al. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer. Folia Histochem Cytobiol. 2001; 39 Suppl 2: 185–186.
  18. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst. 1997; 89(3): 245–250.
  19. Khunamornpong S, Settakorn J, Sukpan K, et al. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand. Asian Pac J Cancer Prev. 2014; 15(24): 10961–10966.
  20. Verma I, Jain V, Kaur T. Application of bethesda system for cervical cytology in unhealthy cervix. J Clin Diagn Res. 2014; 8(9): OC26–OC30.
  21. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005; 38(12): 1103–1111.
  22. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004; 37(2): 112–119.
  23. Demirbag R, Yilmaz R, Erel O, et al. The relationship between potency of oxidative stress and severity of dilated cardiomyopathy. Can J Cardiol. 2005; 21(10): 851–855.
  24. Looi ML, Mohd Dali AZ, Md Ali SA, et al. Oxidative damage and antioxidant status in patients with cervical intraepithelial neoplasia and carcinoma of the cervix. Eur J Cancer Prev. 2008; 17(6): 555–560.
  25. Kim SY, Kim JW, Ko YS, et al. Changes in lipid peroxidation and antioxidant trace elements in serum of women with cervical intraepithelial neoplasia and invasive cancer. Nutr Cancer. 2003; 47(2): 126–130.
  26. Gonçalves TL, Erthal F, Corte CLD, et al. Involvement of oxidative stress in the pre-malignant and malignant states of cervical cancer in women. Clin Biochem. 2005; 38(12): 1071–1075.
  27. Marks MA, Viscidi RP, Chang K, et al. Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women. Cytokine. 2011; 56(3): 798–803.
  28. Tsukui T, Hildesheim A, Schiffman MH, et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res. 1996; 56(17): 3967–3974.
  29. Sharma A, Rajappa M, Saxena A, et al. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer. 2007; 17(4): 879–885.
  30. Kovacic MB, Katki HA, Kreimer AR, et al. Epidemiologic analysis of histologic cervical inflammation: relationship to human papillomavirus infections. Hum Pathol. 2008; 39(7): 1088–1095.
  31. Gupta MM, Jain R, Parashari A, et al. Circulating immune profile in patients with pre-cancer and cancer of the cervix: a cross sectional study among Indian women. Bull Cancer. 1993; 80(10): 852–856.
  32. Ferdeghini M, Gadducci A, Prontera C, et al. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data. Anticancer Res. 1993; 13(3): 709–713.
  33. Koumantakis E, Matalliotakis I, Neonaki M, et al. Soluble serum interleukin-2 receptor, interleukin-6 and interleukin-1a in patients with endometriosis and in controls. Arch Gynecol Obstet. 1994; 255(3): 107–112.
  34. Gadducci A, Ferdeghini M, Malagnino G, et al. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gynecol Oncol. 1994; 52(3): 386–391.
  35. Hildesheim A, Schiffman MH, Tsukui T, et al. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. Cancer Epidemiol Biomarkers Prev. 1997; 6(10): 807–813.
  36. Bais AG, Beckmann I, Lindemans J, et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol. 2005; 58(10): 1096–1100.
  37. Pardo-Govea T, Callejas D, Núñez-Troconis J, et al. [Gamma interferon (IFN-gamma), tumor necrosis factor alpha (TNF-alpha) and interleukins 2, 4 and 6 (IL-2, IL-4, IL-6) in cervical-uterine cells of intraepithelial neoplasia: a preliminary report]. Invest Clin. 2005; 46(1): 5–13.
  38. Kovacic MB, Katki HA, Kreimer AR, et al. Epidemiologic analysis of histologic cervical inflammation: relationship to human papillomavirus infections. Hum Pathol. 2008; 39(7): 1088–1095.